Velaglucerase alfa

维拉西酶α

Report date: 2022/01/14 13:23:58

Base Information

Drug NameVelaglucerase alfa
Drug Alias Namevelaglucerasa alfa维拉苷酶α维拉西酶αGene-activated glucocerebrosidasevelaglucerasum alfa +[13] 
ClassificationBiologics > Protein drugs > Enzyme > Recombinant enzymeBiologics > Protein drugs > Recombinant protein > Recombinant enzyme
Mechanisms of Actionglucocerebroside hydrolysis activatorsGlucosylceramidase replacements
TargetsGlucosylceramide
Therapy Area/IndicationsGaucher's disease type IIIGaucher's disease type IGaucher Disease
Global Approved IndicationsGaucher Disease
Approved Indications in ChinaGaucher Disease
Original Approved Country/TerritoryUnited States
Original Approved Date2010/02/26
Country/TerritoryUnited StatesPolandRomania +[17] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesShire Development Llc
China Registration ClassN/A

Develop Information

Active CompaniesTakeda Pharmaceuticals International AG Ireland BranchShire PharmaceuticalsShire Human Genetic Therapies, Inc +[4] 
Inactive CompaniesTakeda (China) International Trading Co LtdShireDhl Supply Chain (Netherlands) Bv +[6] 
Active IndicationsGaucher Disease
Inactive IndicationsGaucher's disease type IIIGaucher's disease type I

Other Information

ATC CodeA16AB10
Related LinksWikipediaDrugBankKEGG